skip to main content

    Updated Visitor Guidelines

 

MENU

 

Researchers develop new potential drug for rare leukemia

Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.

U-M research on lifetime risk of ovarian cancer may help women make informed decisions

The average lifetime risk of ovarian cancer is approximately 1.37 percent in non-Hispanic white women in the United States, but there are women at substantially higher and lower risk, according to the researchers, led by Celeste Leigh Pearce, associate professor of epidemiology.

Hovnanian Foundation gives U-M $1.65M for adrenal cancer research

The University of Michigan Rogel Cancer Center received a $1.65 million gift from the Hirair and Anna Hovnanian Foundation to fund adrenal cancer research.

Breast Cancer Symptoms

Early breast cancer usually doesn't cause symptoms. But as the tumor grows, it can change how the breast looks or feels.

The common changes include:

  • A lump or thickening in or near the breast or in the underarm area
  • A change in the size or shape of the breast
  • Dimpling or puckering in the skin of the breast
  • A nipple turned inward into the breast
  • Discharge (fluid) from the nipple, especially if it's bloody

Breast Cancer Risk Factors

A risk factor is anything that affects your chance of getting a disease, such as cancer. Most women who have one or more breast cancer risk factors never develop the disease, while many women with breast cancer have no apparent risk factors (other than being a woman and growing older). Even when a woman with risk factors develops breast cancer, it is hard to know just how much these factors may have contributed to her cancer.

News Round-Up for Spring, 2015

The information on this page has expired. To learn about more recent advancements in research at the U-M Rogel Cancer Center, visit our news archive.

Study suggests precision medicine for adrenal cancer

In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.

Meet the Sarcoma Team

The University of Michigan Rogel Cancer Center is built on a foundation of comprehensive, integrated and interdisciplinary specialty care. Although a patient may not see each member of the team, all of the specialists listed below are involved in reviewing patients’ cases and recommending a treatment plan that is coordinated and tailored to the individual patient.

Meet the Neuro-Oncology Team

The University of Michigan Rogel Cancer Center is built on a foundation of comprehensive, integrated and interdisciplinary specialty care. Although a patient may not see each member of the team, all of the specialists listed below are involved in reviewing patients’ cases and recommending a treatment plan that is coordinated and tailored to the individual patient.

Pages